Tag: 300-400

On August 31, 2002, Wang, Jingkang; Liu, Yong; Yin, Qiuxiang published an article.Formula: C17H21ClFN3O4 The title of the article was Studies on the mechanism of primary nucleation of ciprofloxacin hydrochloride monohydrate. And the article contained the following:

A general expression for the relation between induction period and supersaturation was developed based on polynuclear approach. Different mechanism of primary nucleation in solution can be illustrated by the expression. The results of induction period determined by laser scattering method shows that the crystallization of ciprofloxacin hydrochloride monohydrate in water/ethanol or aqueous solution is by the mechanism of primary nucleation followed by one-dimensional diffusion growth, and then one-dimensional continuous or “birth and spread” growth on crystal face. The growth mechanism on the crystal face is affected by temperature and solvent. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Formula: C17H21ClFN3O4

The Article related to ciprofloxacin hydrochloride monohydrate primary nucleation mechanism, Unit Operations and Processes: Separation Processes and other aspects.Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On June 30, 1996, Linnhoff, G. Caldero; Vidal, R. Canals; Ges, J. M. Caldero published an article.Product Details of 86393-32-0 The title of the article was Spectrophotometric study of ciprofloxacin solutions in the presence of ferric ions in acid medium. And the article contained the following:

Spectrophotometric anal. of ciprofloxacin solutions depending on the pH has allowed the acidity constant Ka = (2.80 ± 0.2) × 10-7 (pKa = 6.55 ± 0.05) to be determined Spectrophotometric studies of ciprofloxacin solutions in the presence of ferric ions in acid medium has allowed the presence of a complex to be identified, the formula of the FeCip2+ itself to be established, by Job’s continuous variations method, and the dissociation constant K = (8.77 ± 0.92) × 10-10 (pK=9.06±0.05) to be calculated by two different methods: titration method and Bjerrum’s method of corresponding solutions The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Product Details of 86393-32-0

The Article related to spectrophotometry ciprofloxacin solution ferric chloride, Pharmaceutical Analysis: Natural Drug Materials and other aspects.Product Details of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 31, 1997, Schierholz, Joerg M.; Rump, Alexis; Pulverer, Gerhard published an article.Computed Properties of 86393-32-0 The title of the article was New antiinfectious biomaterials. Ciprofloxacin containing polyurethanes as potential drug delivery systems to prevent foreign-body infections. And the article contained the following:

Device related infections are an increasing problem since foreign materials are used in modern medicine. Ciprofloxacin-HCl salt (CAS 86393-32-0) and lipophilic ciprofloxacin-betaine (Bay o 9867) incorporated into polyurethanes by solvent casting technique were studied in order to develop antiinfectious properties of this biomaterial. Drug release rates, bacterial colonization and morphol. features of the polymer-ciprofloxacin combinations were studied and the physico-chem. mechanisms of the delivery were discussed. Ciprofloxacin salt showed a fast initial release rate, whereas ciprofloxacin-betaine was characterized by a more continuous release behavior. A higher diffusion of the lipophilic ciprofloxacin-betaine in the polymer could be shown as compared to its salt incorporated into the polyurethane. Bacterial colonization to the antibiotic-loaded polyurethanes was inhibited effectively only by preparations showing a slower but more sustained drug release. SEM demonstrated that the polyurethane-antibiotic combination was most homogeneous for ciprofloxacin-betaine. Polyurethane material loaded with ciprofloxacin salt showed crystals at the surface and a granular structure of the polymeric matrix. Crystalline structure of the drug on polymeric surfaces varied with loading concentration and lipophilicity. High homogeneity is required for a sustained and prolonged release and effective inhibition of bacterial colonization. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Computed Properties of 86393-32-0

The Article related to ciprofloxacin release polyurethane prosthetic, biomaterial polyurethane infection inhibition, Pharmaceuticals: Prosthetics and Medical Goods and other aspects.Computed Properties of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 15, 2021, Deng, Yanlin; Liu, Sylvia Yang; Chua, Song Lin; Khoo, Bee Luan published an article.Computed Properties of 86393-32-0 The title of the article was The effects of biofilms on tumor progression in a 3D cancer-biofilm microfluidic model. And the article contained the following:

Components within the tumor microenvironment, such as intratumoral bacteria (IB; within tumors), affect tumor progression. However, current exptl. models have not explored the effects of extratumoral bacteria (EB; outside tumors) on cancer progression. Here, we developed a microfluidic platform to analyze the influence of bacterial distribution on bladder cancer progression under defined conditions, using uropathogenic Escherichia coli. This was achieved by establishing coating (CT) and colonizing (CL) models to simulate the different invasion and colonization modes of IB and EB in tumor tissues. We demonstrated that both EB and IB induced closer cell-cell contacts within the tumor cluster, but cancer cell viability was reduced only in the presence of IB. Interestingly, cancer stem cell counts increased significantly in the presence of EB. These outcomes were due to the formation of extracellular DNA-based biofilms by EB. Triple therapy of DNase (anti-biofilm agent), ciprofloxacin (antibiotic), and doxorubicin (anti-cancer drug) could effectively eradicate biofilms and tumors simultaneously. Our preclin. proof-of-concept provides insights on how bacteria can influence tumor progression and facilitate future research on anti-biofilm cancer management therapies. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Computed Properties of 86393-32-0

The Article related to cancer progression biofilm microfluidic model, antibacterial agents, biofilms, combinatorial therapy, drug screening, microfluidic tumor models, Mammalian Pathological Biochemistry: Oncology and other aspects.Computed Properties of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On November 28, 1996, Ali, Yusuf; Jani, Rajni published a patent.Application In Synthesis of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Antibacterial ophthalmic compositions containing synergistic combination of ciprofloxacin and a polystyrene sulfonic acid polymer. And the patent contained the following:

Aqueous pharmaceutical compositions containing a synergistic combination of ciprofloxacin (I) and a polystyrene sulfonic acid polymer (PSSA) (Markush structure given) are described, wherein the compositions are clear solutions which are comfortable and have sustained-release action. An ophthalmic pharmaceutical solution contained I.HCl.H2O (equivalent to 0.3% as base) 0.35, mannitol 4.4, boric acid 0.3, NaOH and/or HCl 0.3%, 2% PSSA solution 50, and water q.s. 100 mL. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application In Synthesis of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to antibacterial ophthalmic pharmaceutical synergism ciprofloxacin, polystyrene sulfonic acid polymer ophthalmic pharmaceutical, Pharmaceuticals: Formulation and Compounding and other aspects.Application In Synthesis of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 23, 1987, Streuff, Bernd; Luchtenberg, Helmut published a patent.Electric Literature of 86393-32-0 The title of the patent was Pharmaceutical ciprofloxacin preparations. And the patent contained the following:

Pharmaceutical oral compositions contain ciprofloxacin 30.0-95.0, cellulose-based dry binder 4.5-25.0, disintegration enhancers based on starch 0-30.0 and based on cellulose derivatives and(or) polyvinyl pyrrolidone 0.5-10.0, a flowability improver 0-2.0, and a lubricant 0-3.0 weight % for optimal biol. availability and drug stability. Tablets contained ciprofloxacin.H2O 583, Avicel 55, corn starch 72, Polyplasdone XL 30, Aerosil (unpressurized) 5, and Mg stearate 5 mg, coated with Polywax 400 200, HPM-cellulose 6.2, and TiO2 2.0 mg. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Electric Literature of 86393-32-0

The Article related to ciprofloxacin oral pharmaceutical antibacterial, enterobacteria ciprofloxacin oral pharmaceutical, Pharmaceuticals: Formulation and Compounding and other aspects.Electric Literature of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 18, 2022, Gao, Jing; Tan, Shaojie; Wang, Lu published a patent.Synthetic Route of 86393-32-0 The title of the patent was A kind of flexible fiber medicine box for intelligently releasing medicine and its preparation and application.. And the patent contained the following:

The invention relates to a flexible fiber medicine box for intelligently releasing medicine and its preparation and application. The preparation process of the medicine box is as follows: First, the porogen and the macromol. polymer are successively added to the organic solvent and after being mixed uniformly, the nanofiber membrane is prepared by electrospinning as a spinning solution The nanofiber membrane is then put into the Tris-hydrochloric acid buffer solution containing dopamine for modification treatment to obtain a polydopamine-modified nanofiber membrane. Then, the polydopamine-modified nanofiber membrane is placed in a mixed solution for grafting reaction to obtain a switch-loaded fiber membrane. Finally, the switch-loaded fiber membrane is washed and dried to obtain a flexible fiber medicine box. The kit includes porous fibers. PMAA is chem. grafted at the holes on the porous fibers. The prepared medicine box is loaded with medicine, and then the drug release test is carried out in the environment of pH 7.0 to 7.4, the medicine box will not release suddenly within the first 4 to 6 h, and the amount of drug release increases with the pH value of the drug release environment decreased and gradually increased. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Synthetic Route of 86393-32-0

The Article related to ciprofloxacin hydrochloride monohydrate dopamine polydopamine fiber medicine box electrospinning, Pharmaceuticals: Formulation and Compounding and other aspects.Synthetic Route of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Kumar, G. Suresh; Govindan, R.; Girija, E. K. published an article in 2014, the title of the article was In situ synthesis, characterization and in vitro studies of ciprofloxacin loaded hydroxyapatite nanoparticles for the treatment of osteomyelitis.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate And the article contains the following content:

Bioactive materials in combination with antibiotics are widely developed for the treatment of osteomyelitis which play a dual role: as bone substitutes at the affected site and as local drug delivery systems for antibiotic delivery. In the present study, a series of ciprofloxacin loaded hydroxyapatite (HA) nanoparticles with sustained and prolonged release behavior has been synthesized by an in situ precipitation method. The amount of ciprofloxacin loaded on HA nanoparticles can be easily adjusted by changing the initial concentration during the synthesis. It was observed that as the loaded concentration of ciprofloxacin increases the release is sustained and prolonged. The in situ loading of ciprofloxacin onto HA nanoparticles does not significantly affect the bioactivity and cytocompatibility of HA whereas it provides antibacterial activity to HA against S. aureus and E. coli that causes osteomyelitis. Consequently synthesized ciprofloxacin loaded HA nanoparticles can be potential candidates for the treatment of osteomyelitis. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to ciprofloxacin hydroxyapatite nanoparticle osteomyelitis antibacterial biocompatibility, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 19, 2016, Parikh, Nilesh; Hite, William Crawford published a patent.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Topical ciprofloxacin compositions with antibacterial activity. And the patent contained the following:

Embodiments of the invention provide pharmaceutical compositions of ciprofloxacin formulated for topical application to a body surface and for having at least localized antibacterial activity at body sites that comprise, e.g., an ear canal, an oral cavity, a pharyngeal cavity, a nasal cavity, a pulmonary cavity, a vaginal cavity, a rectal cavity, a mucosal surface, a dermal surface, an ophthalmic surface, and a fingernail surface. In some embodiments, the compositions are further formulated for localized anti-inflammatory activity, anti-fungal activity, anti-viral activity, or combinations thereof. Such compositions possess a therapeutically effective amount of a non-betaine form ciprofloxacin (e.g., ciprofloxacin hydrochloride monohydrate); one of a pH adjusting agent and a preservative; water; and a pH from about 5.5 to about 10. In some embodiments, such compositions may be free or free of added skin permeation enhancer and/or contain a betaine form ciprofloxacin. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to ciprofloxacin topical antibacterial antiinflammatory antifungal permeation enhancer, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 19, 2017, Parikh, Nilesh; Hite, William published a patent.COA of Formula: C17H21ClFN3O4 The title of the patent was Topical ciprofloxacin compositions with antibacterial activity. And the patent contained the following:

Embodiments of the invention provide pharmaceutical compositions of ciprofloxacin formulated for topical application to a body surface and for having at least localized antibacterial activity at body sites that comprise, e.g., an ear canal, an oral cavity, a pharyngeal cavity, a nasal cavity, a pulmonary cavity, a vaginal cavity, a rectal cavity, a mucosal surface, a dermal surface, an ophthalmic surface, and a fingernail surface. In some embodiments, the compositions are further formulated for localized anti-inflammatory activity, anti-fungal activity, anti-viral activity, or combinations thereof. Such compositions possess a therapeutically effective amount of a non-betaine form ciprofloxacin (e.g., ciprofloxacin hydrochloride monohydrate); one of a pH adjusting agent and a preservative; water; and a pH from about 5.5 to about 10. In some embodiments, such compositions may be free or free of added skin permeation enhancer and/or contain a betaine form ciprofloxacin. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).COA of Formula: C17H21ClFN3O4

The Article related to ciprofloxacin topical antibacterial antiinflammatory antifungal permeation enhancer, Pharmaceuticals: Formulation and Compounding and other aspects.COA of Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics